Brooklyn ImmunoTherapeutics (BTX)
Gene Editing
Our partners at Factor Bioscience have developed a technology that uses mRNA to express gene-editing proteins. This technology can enable dramatically higher efficiency gene editing, including in primary cells, than other approaches, without using viruses or DNA-based vectors that may cause unwanted mutagenesis. We can use this technology to inactivate one or more genes and/or insert a donor sequence into a genomic safe harbor locus, enabling controlled expression of an exogenous gene.